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Establishing consensus on the diagnosis, treatment and manage-
ment of biliary tract malignancies is a difficult task. Compared
with those of other gastrointestinal cancers, the incidences of
biliary tract malignancies and, in particular, gallbladder cancer
(GBC) are low. Furthermore, there is considerable regional vari-
ation in patterns of disease and presentations. That said, it is
important to review the literature, to solicit expert opinion, and
to format guidelines and treatment recommendations. Consen-
sus views set a standard for medical care that allows for the
comparison of traditional techniques with novel technologies
and lends structure to the development of meaningful clinical
trials that require multi-institution collaboration.
In their consensus statement, Aloia et al.1 cover the spec-
trum of care for patients with premalignant and malignant
GBC, from pathologic staging to the frequent conundrum
implied by the incidental discovery of early-stage cancer and
the less frequent, but dire, presentation of intact and usually
locally advanced GBC. Finally, they review multimodal strate-
gies including chemotherapy and radiation therapy.
The surgical recommendations proposed by the authors1 are,
by and large, well supported. However, some points require
specific highlighting. Firstly, with regard to the proposal for a
comprehensive pathologic evaluation of all presumably benign
gallbladder specimens, it is clear that this should be modulated
based on the regional incidence of GBC and individualized to
patient risk factors. The point is well made, however, that,
particularly in the case of incidentally discovered GBC, providers
are often left with inadequate pathologic information regarding
the location of the tumour (e.g. free peritoneal surface versus
liver side, fundus versus infundibulum, and the distance from or
involvement of the cystic duct stump). Each of these items is
critical to the ascertaining of patient prognosis and to determin-
ing the approach to be taken in any subsequent surgery.
Secondly, there is considerable debate regarding the size of a
gallbladder polyp that mandates cholecystectomy. Although
some literature suggests that the risk for malignancy rises after
8 mm, the weight of the evidence supports the recommenda-
tion of a 1-cm cut-off. It should be noted that the risk for
cholecystectomy has diminished and, if medical comorbidities
and prior surgery are not prohibitive, a more aggressive
approach to gallbladder polyps may be justified.
Thirdly, the consensus statement has boldly set the goal for
portal lymphadenectomy at the recovery and identification of
six lymph nodes. Although the spirit of this recommendation
is clear (in the majority of GBC operations, the first goal is to
stage the patient), we know that most large series from reputa-
ble oncologic surgeons report the recovery of a median of two
or three lymph nodes.2 The discrepancy between our observed
and expected nodal recovery is likely to result from the fact
that a properly performed portal lymphadenectomy resects the
lymphatic tissues en bloc, and frequently the nodes are contig-
uous and considered to be one by the pathologist. This reality
highlights the need for surgeon–pathologist communication
and even suggests that the surgeon should participate in the
grossing of lymphadenectomy specimens. It also implies that,
to properly stage a GBC patient, surgeons should aim to
remove more than just the nodal tissue in the immediate area
of the porta hepatis, and should more frequently include the
aortocaval and coeliac regions.
In their consensus statements relating to the multimodal treat-
ment of GBC patients, Aloia et al.1 posit a role for chemotherapy
and/or radiation therapy in the adjuvant setting. They clearly
acknowledge the lack of Level I evidence to support such a state-
ment, and admit that much of what has been published in this
arena refers to data established prior to the era of extended
resections and gemcitabine-based combination chemotherapy.
They do, however, appropriately state the importance of multi-
modal therapy in the high-risk population of resected GBC
patients with known nodal disease or advanced tumour stage.
With regard to the role of neoadjuvant therapy in localized
GBC and given the paucity of data clearly supporting the
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efficacy of adjuvant therapy, we agree that clinical trials are
required. Patients with N1 disease often develop distant metas-
tases, rendering local therapies such as surgery and radiation
futile. In addition, these patients are known to be at high risk
for recurrence even after a complete extended resection.
Preoperative therapy could help to select patients with tumour
biology that would benefit most from surgical approaches.
Furthermore, the formal evaluation of neoadjuvant chemother-
apy and chemoradiation in a clinical trial might clarify the
added benefit of chemoradiation in this population in the
context of gemcitabine and platinum chemotherapy.
The second consensus statement stresses the need for adju-
vant therapy in patients with a negative margin (R0) resection
but with disease staging of >T2 or >N1. Recurrence-free sur-
vival in these patients is known to be quite poor, which
implies a need for effective postoperative therapy. However,
until recently, this had not been investigated in a prospective
manner. Several randomized adjuvant trials that compare che-
motherapy alone with observation are completing accrual in
Europe and are anticipated to report their findings in the next
year. These will provide the best evidence to date and help
guide the next steps for practice and trials. The SWOG S0809
non-randomized Phase II study investigated the combination
of gemcitabine and capecitabine followed by chemoradiation in
the adjuvant setting in high-risk GBC and extrahepatic cholan-
giocarcinoma and showed quite encouraging outcomes in
terms of 2-year overall survival in both negative margin and
positive margin populations.3 A North American-based Phase
III study evaluating the addition of radiation to doublet che-
motherapy in comparison with doublet chemotherapy alone in
this same resected population is under consideration.
Aloia et al.1 next argue for a benefit to chemoradiation in
margin-positive resected GBC. Although this may be appropriate
in some patients, again, supporting prospective data are lacking.
Furthermore, in patients with a margin-positive resection and
N1 disease, the need for chemotherapy to decrease the risk for
systemic relapse may trump the benefit of adjuvant chemoradia-
tion to prevent local recurrence. Patients should be appropriately
stratified based on all of their high-risk pathologic features so
that the sequencing of multimodal therapy will be of maximum
benefit.
In their final consensus statement, the authors1 comment on
the benefit of combination chemotherapy in patients with
advanced disease. Here, there is clear Level I evidence that a
combination of gemcitabine and cisplatin in patients with good
performance status improves overall survival, progression-free
survival and disease control rates compared with gemcitabine
alone. Patients with a poor performance status will be unlikely
to tolerate combination therapy, and thus the recommendation
for single-agent gemcitabine is appropriate. With gemcitabine
and cisplatin as the new backbone for all future clinical trials,
it will be interesting to discover the roles other cytotoxics, tar-
geted therapies and immune therapies may play in the treat-
ment of advanced GBC.
In summary, this consensus document covers the breadth of
issues relating to the multidisciplinary care of patients with
gallbladder malignancy. Although some areas lack high-level
evidence to support recommendations, the guidelines provided
represent our best understanding of the state of the field and
propose logical criteria on which to base future investigations.
Conflicts of interest
None declared.
References
1. Aloia TA, Jarufe N, Javle M, Maithel SK, Roa JC, Adsay V et al. (2015)
Gallbladder Cancer: expert consensus statement. HPB 70:681–690 .
2. Pawlik TM, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A et al.
(2007) Incidence of finding residual disease for incidental gallbladder
carcinoma: implications for re-resection. J Gastrointest Surg 11:
1478–1486.
3. Ben-Josef E, Guthrie K, El-Khoueiry AB, Corless CL, Zalupski MM,
Lowy AM et al. (2015) SWOG S0809: a phase II intergroup trial of adju-
vant capecitabine and gemcitabine followed by radiotherapy and con-
current capecitabine and in extrahepatic cholangiocarcinoma and
gallbladder carcinoma. J Clin Oncol:; pii: JCO.2014.60.2219 [Epub
ahead of print].
HPB 2015, 17, 664–665 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 665
